Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | SPR | P35270 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 5/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396980 | 0.83 | MGLL (0.51) | MEN1KMT2AMGLL | |
| SCHEMBL3243551 | 0.77 | CYP2C9 (0.53) | MEN1KMT2ACYP2C9CYP2C19MAPK14 | |
| SCHEMBL1114307 | 0.75 | CYP2C9 (0.53) | MEN1KMT2ACYP2C9CYP2C19MAPK14 | |
| SCHEMBL3243691 | 0.73 | MEN1 (0.57) | MEN1KMT2ACYP2C9CYP2C19MAPK14 | |
| SCHEMBL3243964 | 0.73 | SCD5 (0.62) | MEN1KMT2ACYP2C9CYP2C19MAPK14 | |
| SCHEMBL12263138 | 0.73 | CA12 (0.44) | — | |
| SCHEMBL693466 | 0.72 | CYP2C9 (0.54) | MEN1KMT2ACYP2C9CYP2C19MAPK14 | |
| SCHEMBL26819132 | 0.72 | CYP2C9 (0.54) | MEN1KMT2ACYP2C9CYP2C19MAPK14 | |
| SCHEMBL3243718 | 0.71 | CYP2C9 (0.53) | MEN1KMT2ACYP2C9CYP2C19MAPK14 | |
| SCHEMBL8391498 | 0.71 | CYP2C9 (0.53) | MEN1KMT2ACYP2C9CYP2C19MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | claimed |
| EP-2341776-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2011-07-13 | — | — | EP | claimed |
| WO-2010033626-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-03-25 | — | — | WO | claimed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| EP-2341776-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| WO-2010033626-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | MEN1 2895/4885KMT2A 4715/4885CYP2C9 1243/4885 |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | CFTR, PKD1, PKD2 | MEN1 2606/4885KMT2A 4709/4885CYP2C9 1359/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | MEN1 2895/4885KMT2A 4715/4885CYP2C9 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.